Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Study of Ixekizumab (LY2439821) in Children With Juvenile Idiopathic Arthritis Categories of Enthesitis-related Arthritis (Including Juvenile Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04527380
Recruitment Status : Recruiting
First Posted : August 26, 2020
Last Update Posted : June 23, 2022
Sponsor:
Information provided by (Responsible Party):
Eli Lilly and Company

Study Description
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
The reason for this study is to see if the study drug ixekizumab is safe and effective in children with juvenile idiopathic arthritis (JIA) categories of enthesitis-related arthritis (ERA) (including juvenile onset ankylosing spondylitis [JoAS]) and juvenile psoriatic arthritis (JPsA).

Condition or disease Intervention/treatment Phase
Juvenile Psoriatic Arthritis Enthesitis Related Arthritis Drug: Ixekizumab Drug: Adalimumab Phase 3

Study Design
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 100 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Multicenter, Open-label, Efficacy, Safety, Tolerability, and Pharmacokinetic Study of Subcutaneous Ixekizumab With Adalimumab Reference Arm, in Children With Juvenile Idiopathic Arthritis Subtypes of Enthesitis-related Arthritis (Including Juvenile-Onset Ankylosing Spondylitis) and Juvenile Psoriatic Arthritis
Actual Study Start Date : April 13, 2021
Estimated Primary Completion Date : July 31, 2023
Estimated Study Completion Date : April 24, 2028

Resource links provided by the National Library of Medicine


Arms and Interventions
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Arm Intervention/treatment
Experimental: Ixekizumab
Ixekizumab given subcutaneously (SC).
 Drug: Ixekizumab
Administered SC
Other Name: LY2439821
Active Comparator: Adalimumab
Adalimumab given SC. Participants may have the option to switch to ixekizumab given SC during the open label extension period.
 Drug: Adalimumab
Administered SC


Outcome Measures
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Percentage of Participants Achieving Juvenile Idiopathic Arthritis (JIA) American College of Rheumatology (ACR) 30 [ Time Frame: Week 16 ]
    Percentage of Participants Achieving JIA ACR 30


Secondary Outcome Measures :
  1. Percentage of Participants Achieving JIA ACR 30/50/70/90/100 [ Time Frame: Week 0 up to Week 104 ]
    Percentage of Participants Achieving JIA ACR 30/50/70/90/100

  2. Change from Baseline in Psoriasis Area and Severity Index (PASI) for JPsA Participants with at Least 3% Body Surface Area (BSA) at Baseline [ Time Frame: Baseline, up to Week 104 ]
    Change from Baseline in PASI for JPsA Participants with at Least 3% BSA at Baseline

  3. Change from Baseline in Leeds Enthesitis Index (LEI) for Participants with Enthesitis at Baseline [ Time Frame: Baseline, up to Week 104 ]
    Change from Baseline in LEI for Participants with Enthesitis at Baseline

  4. Percentage of Participants with Disease Flare (Flare Defined as Worsening of ≥30% from Baseline in at Least 3 of the 6 JIA ACR Core Set Criteria and an Improvement of ≥30% in No More than 1 of the Criteria) [ Time Frame: Week 0 up to Week 104 ]
    Percentage of Participants with Disease Flare (Flare Defined as Worsening of ≥30% from Baseline in at Least 3 of the 6 JIA ACR Core Set Criteria and an Improvement of ≥30% in No More than 1 of the Criteria)

  5. Pharmacokinetics (PK): Trough Concentrations (Ctrough) of Ixekizumab [ Time Frame: Week 16 ]
    Pharmacokinetics (PK): Ctrough of Ixekizumab

  6. Number of Participants with Anti-Ixekizumab Antibodies [ Time Frame: Week 0 up to Week 104 ]
    Number of Participants with Anti-Ixekizumab Antibodies


Eligibility Criteria
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   2 Years to 17 Years   (Child)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Participants must have active juvenile idiopathic arthritis (categories of enthesitis related arthritis or juvenile psoriatic arthritis)
  • Participants must have weight of at least 10 kilograms (Kg), age starting at 2 years for participants with juvenile psoriatic arthritis and starting at 6 years for participants with enthesitis related arthritis
  • Participants must have all immunizations up-to-date in agreement with current immunization guidelines, in the opinion of the investigator

Exclusion Criteria:

  • Participants must not have active or history of inflammatory bowel disease
  • Participants must not have active uveitis
  • Participants must not have active or latent tuberculosis
  • Participants must not have an active infection
  • Participants must not have concurrent use of biologic agents for the treatment of the juvenile idiopathic arthritis
Contacts and Locations
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04527380


Contacts
Layout table for location contacts
Contact: There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 clinicaltrials.gov@lilly.com

Locations
Show Show 48 study locations
Sponsors and Collaborators
Eli Lilly and Company
Investigators
Layout table for investigator information
Study Director: Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM -5 PM Eastern time (UTC/GMT - 5 hours, EST) Eli Lilly and Company
More Information
Go to 
Top of Page Study Description Study Design Arms and Interventions Outcome Measures Eligibility Criteria Contacts and Locations More Information
Additional Information:

Layout table for additonal information
Responsible Party: Eli Lilly and Company
ClinicalTrials.gov Identifier: NCT04527380    
Other Study ID Numbers: 16694
I1F-MC-RHCG ( Other Identifier: Eli Lilly and Company )
2018-000681-10 ( EudraCT Number )
First Posted: August 26, 2020    Key Record Dates
Last Update Posted: June 23, 2022
Last Verified: June 17, 2022
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement.
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Clinical Study Report (CSR)
Time Frame: Data are available 6 months after the primary publication and approval of the indication studied in the US and EU, whichever is later. Data will be indefinitely available for requesting.
Access Criteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement.
URL: https://vivli.org/

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes
Additional relevant MeSH terms:
Layout table for MeSH terms
Spondylitis
Arthritis
Arthritis, Psoriatic
Spondylitis, Ankylosing
Arthritis, Juvenile
Enthesopathy
Joint Diseases
Musculoskeletal Diseases
Bone Diseases, Infectious
Infections
Bone Diseases
Spinal Diseases
Spondylarthritis
Spondylarthropathies
Psoriasis
 Skin Diseases, Papulosquamous
Skin Diseases
Ankylosis
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Tendinopathy
Muscular Diseases
Tendon Injuries
Wounds and Injuries
Adalimumab
Ixekizumab
Anti-Inflammatory Agents
Antirheumatic Agents